Evogene (NASDAQ:EVGN) announced its earnings results on Tuesday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.01, Fidelity Earnings reports. Evogene had a negative return on equity of 42.72% and a negative net margin of 2,247.50%.
Shares of NASDAQ:EVGN opened at $3.68 on Thursday. The business’s 50-day moving average is $4.07 and its 200 day moving average is $4.92. Evogene has a 1 year low of $0.94 and a 1 year high of $10.24. The firm has a market capitalization of $94.76 million, a P/E ratio of -4.49 and a beta of 1.28.
Separately, Zacks Investment Research raised Evogene from a “sell” rating to a “hold” rating in a research report on Tuesday, May 4th.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements.
Read More: What is the definition of arbitrage?